Abstract Purpose: Loss of chromosome arms 1p and 19q is a molecular feature of oligodendroglial tumors characterized by responsiveness to chemotherapy and a favorable prognosis. The purpose of this study was to evaluate the prognostic significance of polysomy of chromosomes 1 and 19 in the setting of 1p/19q codeletion. Experimental Design: We analyzed 64 anaplastic oligodendrogliomas with 1p/19q loss or maintenance diagnosed at Massachusetts General Hospital and Brigham and Women's Hospital from 1996 to 2005; fluorescence in situ hybridization for 1p/19q and Ki-67 immunohistochemistry was done. Polysomy was defined as more than two 1q and 19p signals in >30% of the cells with concurrent 1p/19q deletion. Tumors were divided into groups based on their 1p/19q status and compared for progressionfree survival, overall survival, and 5-year survival probabilities.
lomustine, and vincristine (7) (8) (9) (10) , and to temozolomide (11, 12) , as well as to radiotherapy (13) . 1p/19q status thus represents a reliable marker of biological behavior, and testing for 1p/19q loss is now considered standard of care (14, 15) . Nonetheless, despite the fact that most anaplastic oligodendrogliomas with 1p/19q codeletion respond to therapy, most recur and require additional treatment. Therefore, markers to detect tumors with higher risk for early recurrence within the 1p/19q codeleted population would be clinically useful. In this regard, molecular markers that can potentially identify higher-risk tumors within subgroups defined by 1p/19q loss and maintenance have been proposed (10) .
Although numerous studies have confirmed the significance of 1p/19q loss as a predictor of response to therapy in anaplastic oligodendroglioma, the genes responsible for tumorigenesis and/or therapeutic sensitivity have not been identified (16) (17) (18) (19) (20) (21) (22) . The exact mechanism of the loss has also been enigmatic, but recent studies suggest that loss of 1p and 19q is mediated by formation of a balanced whole arm translocation involving chromosomes 1 and 19, with subsequent loss of the derivative chromosome der(1;19)(p10;q10) and maintenance of the der(1;19)(q10;p10) (23, 24) . In clinical practice, PCR and fluorescence in situ hybridization (FISH) are the most commonly used methods and have been considered to generally provide equivalent prognostic information. However, studies using FISH have noted that, in addition to the loss of 1p and 19q, a subset of tumors possess additional copies of these chromosomes (5, 25) and that this was more common in anaplastic and recurrent tumors. Our anecdotal observations of occasional cases of rapidly progressing anaplastic oligodendroglioma with 1p/19q loss and extra copies of 1p and 19q using FISH, prompted us to explore polysomy in a larger cohort of anaplastic oligodendrogliomas.
In this study, we have quantitated 1p and 19q signals by FISH in a cohort of anaplastic oligodendroglioma to detect polysomy of chromosomes 1 and 19. Progression-free and overall survival was determined for tumors with and without loss of 1p/19q; within the codeleted group, we compared tumors with and without polysomy. To analyze if polysomy is a surrogate marker for increased mitotic activity, we also compared proliferation indices in 1p/19q codeleted anaplastic oligodendroglioma with and without polysomy.
Materials and Methods
Medical chart review, histopathologic analysis and molecular studies were performed on patients with newly diagnosed anaplastic oligodendroglioma, WHO grade III, seen at the Massachusetts General Hospital and Brigham and Women's Hospital between 1996 and 2005, for whom clinical data were available. None of the patients had a history of a previous low-grade tumor or chemoradiation. Of the 87 patients with primary anaplastic oligodendroglioma in our database, 64 patients had either a loss or maintenance of chromosomes 1p and 19q by the report and further analyses were limited to this cohort, whereas patients with loss of only 1p or of 19q or only polysomy were excluded because of a small sample size of each subgroup. Clinical presentation, neuroradiologic imaging, extent of surgery, adjuvant therapy, and follow-up were determined from medical records. Approval from the Dana-Farber/Harvard Cancer Center Institutional Review Board was obtained before the initiation of this study.
Progression was defined either radiologically by enlargement of the existing lesion or development of a new lesion or by clinical deterioration attributed to the tumor. A new lesion in the brain consistent with tumor based on imaging and clinical symptoms was considered sufficient to make the diagnosis of progressive disease when biopsy or resection was not considered clinically indicated. Positive response to salvage therapy was defined as either stable disease or a positive clinical and/or radiographic response.
Progression-free survival was defined as the time from diagnosis to progression as defined above or the time to death if death occurred without progression. Overall survival was defined as the time from the initial diagnosis to death.
Histopathology and immunohistochemistry. All studies were done on formalin-fixed, paraffin-embedded tissues. Sections were stained with H&E and were reviewed, and diagnosis and grade were confirmed by two neuropathologists independently (M. Snuderl; K.L. Ligon) using WHO 2007 criteria (3). Low-grade oligodendrogliomas and tumors with astrocytic components were excluded.
A representative paraffin block was selected for immunohistochemical studies. A rabbit monoclonal anti-Ki-67 IgG antibody (clone 30-9; Ventana Medical Systems), supplied and prediluted by the manufacturer, was used for the study. Immunohistochemistry was done on BenchMark XT automated tissue staining systems (Ventana Medical Systems, Inc.) using validated protocols and tonsil as a positive control. Tissues were counter stained with hematoxylin. In the areas of the highest expression, 500 cells were counted (40× objective), and a labeling index was calculated as the percentage of positive tumor cells.
FISH. FISH was done for 1p and 19q loss, as described previously (26) . Briefly, 5-μm sections of formalin-fixed, paraffin-embedded tumor material were prepared, and an H&E section was reviewed to select regions for hybridization that contain most tumor cells. Two separate dual-color FISH assays were done; one slide used Bacterial Artificial Chromosome probes RP11-558F24 (chromosome 1p; labeled orange) and RP11-45903 (chromosome 1q; labeled green), and the second slide used RP11-75H6 (chromosome 19p; labeled green) and RP11-293G10 (chromosome 19q; labeled orange). Signal quantitation of 100 nuclei was used to generate a 1p/1q ratio and a 19q/19p ratio. The total number of signals was counted, and a ratio of 1p:1q (or 19q:19p) of <0.75 was diagnosed as loss and ≥0.75 as maintenance, which are the scoring parameters also used in our clinical practice. The tumor was considered to have polysomy if ≥30% of nuclei showed three or more signals for 1q and 19p.
Statistics. Based on FISH results, patients were divided into the following groups for survival analyses: (a) loss of 1p/19q with polysomy, (b) loss of 1p/19q without polysomy, and (c) maintenance of 1p/19q. Groups were then compared for progression-free survival, overall survival, 5-y progression-free survival, 5-y overall survival, Ki-67 labeling index, sex, and tumor location.
Survival was estimated using the Kaplan-Meier method. The three group comparisons were as follows: (a) anaplastic oligodendroglioma with 1p/19q loss versus anaplastic oligodendroglioma with 1p/19q maintenance, (b) anaplastic oligodendroglioma with 1p/19q loss and polysomy versus anaplastic oligodendroglioma with 1p/19q loss without polysomy, and (c) anaplastic oligodendroglioma with 1p/19q loss and polysomy versus anaplastic oligodendroglioma with 1p/19q maintenance. Bivariate Cox regression models were fit with 1p/19q loss and each known prognostic factor. Because of the small sample size, larger multivariate models were not considered.
For 5-y progression-free survival and overall survival, the KaplanMeier survival probabilities at 60 mo were compared between groups using a Z test based on their approximate normality. The comparisons were conducted among the groups in the same manner as the above analysis. For subjects who progressed, survival from the time of progression was also compared between groups.
A Wilcoxon rank sum statistical was used to determine the difference in mitotically active fraction (Ki-67 positive cells) between anaplastic oligodendroglioma with 1p/19q loss with and without polysomy. Fisher's exact tests were used to determine group differences in sex and tumor location. Associations among prognostic variables were assessed using Fisher's exact test (two binary variables), Spearman r (continuous variables), and the Wilcoxon rank sum test (one binary and one continuous variable).
A Bonferroni correction was applied to adjust for the three comparisons undertaken; P values were multiplied by three and compared with a threshold of 0.05 for significance.
Translational Relevance
1p/19q chromosomal loss is present in anaplastic oligodendrogliomas with improved response to chemotherapy and improved survival. We report that chromosomal polysomy in anaplastic oligodendrogliomas with 1p/19q loss identifies tumors with a high-risk potential for recurrence. Polysomy does not correlate with Ki-67 staining and thus seems independent of proliferation activity. Polysomy assessment, as a novel prognostic marker, can be rapidly introduced into the clinical practice because fluorescence in situ hybridization is one of the most common molecular methods for 1p/19q status evaluation.
Results
Analysis of polysomy in anaplastic oligodendrogliomas. FISH analysis of 64 anaplastic oligodendrogliomas revealed 1p/19q loss in 46 (72%) of tumors and 1p/19q maintenance in 18 (28%). Average 1q and 19p FISH signals per cell for those cases with 1p/19q loss were calculated and divided into groups with and without polysomy. 1p and 19q signals were not used in the calculation because of their known deletion (polysomy of those chromosomal regions would be two or more copies, which is more difficult to enumerate). Of 46 anaplastic oligodendrogliomas with 1p/19q loss, 19 (41%) showed polysomy and 27 (59%) showed no polysomy. Representative images are shown in Fig. 1A to C. Within the group of anaplastic oligodendroglioma with 1p/19q loss and polysomy, eight cases showed tetraploidy, that is, two signals for 1p/19q and four signals for 1q/ 19p in most of the nuclei with polysomy. However, 11 cases showed high intratumor variability in the number of signals ranging from three to six signals for 1q/19p and one to five signals for 1p/19q. This high variability among tumors as well as within each tumor precluded further substratification in a cohort of this size. Intratumor variability in the number of signals is shown in Fig. 1C .
For the 64 subjects with anaplastic oligodendroglioma in this study, the median age at diagnosis was 44 years (range, 17-78 years), and there was no difference in age between patients with maintenance or loss of 1p/19q with or without polysomy. Thirty-five patients were male (55%), and 29 patients were female (45%). In the subgroup of patients with concurrent 1p/19q loss and polysomy, there was a male predominance (68% versus 32%), whereas the subgroup of patients with 1p/19q maintenance showed a slight female predominance (56% versus 44%); however, differences were not significant. In the subgroup of patients with 1p/19q loss without polysomy, the male: female ratio was 1:1. Forty-five patients (70%) had Karnofsky performance score 90 to 100, and there was no difference between anaplastic oligodendroglioma with 1p/19q loss and with maintenance. Younger age was associated with better Karnofsky performance score (P = 0.0147). There was a statistically significant difference in Karnofsky performance score between anaplastic oligodendroglioma with 1p/19q loss with and without polysomy (P = 0.0318) because of 30% of patients with anaplastic oligodendroglioma and 1p/19q loss without polysomy having Karnofsky performance score of ≤80 versus only 10% of those with polysomy. The clinical and pathologic data are summarized in Tables 1 and 2 .
Forty-eight tumors (75%) were centered in the frontal lobe, 11 (17%) in the temporal lobe, 3 (5%) in the parietal lobe, and 2 (3%) in diencephalon; no tumors were in the occipital lobe. Tumors in the frontal lobe showed 1p/19q loss in 85% of cases, whereas 73% of tumors in the temporal lobe had maintenance of 1p/19q. Both tumors in the diencephalon showed preservation of 1p/19q. There was a significant association between frontal lobe location and loss of 1p/19q and temporal lobe and maintenance of 1p/19q (P < 0.003), as previously reported (7, 27) .
The clinical management of patients in this cohort involved surgical gross total resection in 25 cases (39%) and subtotal resection in 33 cases (52%), and biopsy only was done in six cases (9%). Fifty patients (78%) received adjuvant radiation therapy, and 55 patients (86%) received adjuvant chemotherapy. The first-line chemotherapy was composed of either procarbazine, lomustine, and vincristine (28 patients), or temozolomide (27 patients). Median progression-free survival was 50 months (range, 2-132 months) for the entire cohort, and median overall survival was 123 months (range, 5-158 months).
In all cases, histopathologic evaluation revealed cytologic features of oligodendroglioma with round nuclei and perinuclear halos but with high cell density, marked nuclear atypia, and brisk mitotic activity. Branching capillary architecture was still recognizable, although all cases showed variable degree of microvascular proliferation. Tumor necrosis was not observed. Representative images are shown in Fig. 1D and F.
Anaplastic oligodendrogliomas with 1p/19q loss have longer progression-free survival and overall survival. We compared the survival of 46 patients with anaplastic oligodendroglioma and 1p/19q loss (irrespective of the polysomy status) with 18 patients with anaplastic oligodendroglioma with 1p/19q maintenance. Of the 46 anaplastic oligodendrogliomas with 1p/19q loss, 27 recurred (59%) with a median progression-free survival of 81 months, whereas 16 (89%) of 18 anaplastic oligodendrogliomas with 1p/19q maintenance recurred with a median progression-free survival of 21 months. Twenty-two patients recurred and died during the time of the follow-up (34%), including 13 (72%) of 18 patients with maintenance of 1p/19q and 9 (20%) of 46 patients with deletion of 1p/19q. Patients with anaplastic oligodendroglioma with 1p/19q loss had significantly better progression-free survival and overall survival than patients with maintenance of 1p/19q (progression-free survival, 81 versus 21 months, respectively; P = 0.0009; overall survival, 158 versus 41 months, respectively; P < 0.0003; Fig. 2 ; Table 1 ).
Prognosis at 5 years was significantly better for patients with 1p/19q loss in terms of progression-free and overall survival.
The 5-year overall survival probability for patients with loss of 1p/19q was 0.904 but only 0.389 for patients with preserved 1p/19q (P < 0.0003), and the 5-year progression-free probability for patients with loss of 1p/19q was 0.573 but only 0.111 when 1p/19q was preserved (P < 0.0003; Table 3 ).
Anaplastic oligodendrogliomas with concurrent 1p/19q loss and polysomy have earlier recurrence. During the follow-up period, 15 (79%) of 19 patients with 1p/19q loss and polysomy progressed with progression-free survival ranging between 5 to 96 months (median progression-free survival, 47 months), whereas within the subgroup of the patients with 1p/19q loss without polysomy, only 12 (44%) of 27 progressed, with progression-free survival ranging between 16 to 132 months (median progression-free survival, 87 months). This difference reached statistical significance (P = 0.0048). Although patients with 1p/19q deletion and polysomy had slightly better progression-free survival than those with 1p/19q maintenance, this difference was not significant (P = 0.303; Fig. 2) . Similarly, the 5-year progression-free probability was significantly worse for patients who showed 1p/19q loss with polysomy (0.351) when compared with those with 1p/19q loss without polysomy (0.747; P = 0.009; Table 3 ).
Despite the shorter progression-free survival seen in patients with 1p/19q deletion with polysomy compared with those with 1p/19q codeletion but without polysomy, there was no Abbreviations: AO, anaplastic oligodendroglioma; KPS, Karnofsky performance score; GTR, gross total resection; STR, subtotal resection; Bx, biopsy only; PFS, progression-free survival; OS, overall survival; 95% CI, 95% confidence interval; N/A, quantity not estimable with the current data; -, variable not tested. *P values are for comparisons between 1p/19q loss and 1p/19q maintenance groups, adjusted for additional multiple testing by multiplying by 3.
significant difference in overall survival between the two groups (101 versus 158 months, respectively; P = 0.303). Interestingly, in a bivariate Cox model in which overall survival was adjusted for Karnofsky performance score, there was a decrease in hazard ratio (from 0.246 to 0.316) for anaplastic oligodendroglioma with 1p/19q codeletion and polysomy compared with anaplastic oligodendroglioma with codeletion without polysomy. Although the adjusted P value was not significant, these results confirm the trend of worse overall survival for anaplastic oligodendroglioma with codeletion and polysomy and suggest that the apparent difference in overall survival might become statistically significant with a larger cohort size. Overall survival for anaplastic oligodendroglioma with maintenance of 1p/19q was significantly worse than overall survival for anaplastic oligodendroglioma with 1p/19q loss and polysomy (P = 0.0172; Fig. 2 ).
The 5-year overall survival probability for patients with loss of 1p/19q and polysomy (0.892) was not significantly worse than for patients with 1p/19q loss and without polysomy (0.913; P = 0.209; Table 3 ).
Recurrent anaplastic oligodendrogliomas with 1p/19q loss with or without polysomy respond to therapy. Treatment at the time of presentation is summarized in Tables 1 and 2 . All 43 patients whose tumors recurred during the follow-up period were treated with additional chemotherapy and/or radiation. Chemotherapy at the time of recurrence was predominantly temozolomide (32 patients); two patients received 1,3-bis(2-chloroethyl)-1-nitrosourea, and seven patients received a wide variety of experimental protocols, including bevacizumab, rapamycin, thalidomide, etoposide, and erlotinib, without notable benefit. Five patients received radiation at the time of recurrence, either alone (n = 2) or in combination with chemotherapy (n = 3). The median survival from recurrence was 26 months.
In patients with 1p/19q loss, 18 of 27 had a positive response to salvage therapy. This response rate was similar for tumors with and without polysomy (10 of 15 and 8 of 12 patients, respectively), and there was no difference in survival from recurrence to death between both groups. In contrast, only 3 (19%) of 16 patients with recurrent anaplastic oligodendroglioma with 1p/19q maintenance had a positive response to secondline therapy. Their survival from recurrence to death was significantly lower than of patients with anaplastic oligodendroglioma with 1p/19q loss (P = 0.013; Table 1 ). The difference in survival from recurrence to death between anaplastic oligodendroglioma with 1p/19q maintenance and 1p/19q loss and polysomy was marginally significant (P = 0.054).
Presence of polysomy does not correlate with Ki-67. The mean Ki-67 score for anaplastic oligodendroglioma with 1p/19q loss and polysomy was 14.1% (range, 2-40%) and was not different from the proliferation activity of anaplastic oligodendroglioma with 1p/19q loss and no polysomy (Ki-67 mean proliferation score, 13.8%; range, 2-55%) There was no correlation between polysomy and proliferation activity measured by Ki-67, and there was no association between Ki-67 and survival (Table 2 ; Fig. 1E and G) . 
Discussion
Our results show that polysomy is a predictor of earlier recurrence in anaplastic oligodendroglioma with 1p/19q loss. Although concurrent polysomy and 1p/19q loss has been noted before in oligodendrogliomas (5, 25) , its prognostic significance has not been evaluated. For example, Fallon et al. (5) observed polysomy in 14% of their 1p/19q deleted tumors and noted that it was more frequent in recurrent and high-grade tumors. We limited our study to pure anaplastic oligodendroglioma with either concurrent 1p/19q loss or maintenance of 1p and 19q. Although some polysomic cases are purely In the entire cohort of 64 patients, 1p/19q maintenance is associated with decreased progression-free survival (2A; P = 0.009), as well as overall survival (2B; P < 0.0003), when compared with anaplastic oligodendrogliomas with 1p/19q loss. Anaplastic oligodendrogliomas with 1p/19q loss and polysomy have significantly worse progression-free survival than anaplastic oligodendroglioma with 1p/19q loss without polysomy (2C; P = 0.0048). Difference in progression-free survival between anaplastic oligodendroglioma with 1p/19q maintenance and 1p/19q loss with polysomy was not significant (2C; P = 0.303), whereas the overall survival of anaplastic oligodendroglioma with 1p/19q loss and polysomy was significantly better than anaplastic oligodendroglioma with 1p/19q maintenance (2D; P = 0.0172). The difference in overall survival between 1p/19q codeleted anaplastic oligodendroglioma with and without polysomy was not significant (2D; P = 0.303). All P values are multiplied by 3 to adjust for multiple testing.
tetraploid, many tumors show high intratumor variability in the number of copies, which precludes their further substratification based on copy number at least within a cohort of this size. In addition, other less common patterns were seen in our practice and by others (25) , such as isolated deletion of either 1p or 19q and/or isolated polysomy of chromosome 1 or 19. Because of the limited number of cases, we were not able to evaluate significance of these less common variants. The mechanism that leads to polysomy is not clear. We compared Ki-67 activity of anaplastic oligodendroglioma with 1p/ 19 loss with and without polysomy to investigate if polysomy is reflective of higher proliferation activity. Multiple previous studies have evaluated the prognostic significance of Ki-67 activity in oligodendrogliomas, and although there is a relative consensus that high proliferation activity measured by Ki-67 is an independent prognostic marker for low-grade oligodendroglioma, Ki-67 does not seem to add additional prognostic information in anaplastic oligodendroglioma (28) (29) (30) . Our data confirm that there is no prognostic value of Ki-67 in anaplastic oligodendroglioma and, as such, suggest that polysomy is a marker that is independent of proliferative activity. However, because Ki-67 staining is variable among different laboratories and dependent on many variables, including the quality of tissue fixation, there is still a possibility that polysomy as detected by FISH represents a more sensitive and reliable method for detecting mitotic activity. Another possible explanation for why polysomy cases show earlier recurrence is that these tumors are in fact glioblastomas with oligodendroglial component. This remains a formal possibility despite careful histologic review because of possible tumor sampling bias. Finally, it is possible that polysomy is present in tumors with increased genomic instability and that this instability then correlates with tumor progression.
In clinical practice, PCR-based loss of heterozygosity studies and FISH are the most commonly used methods to detect 1p/ 19q loss, although FISH may be more frequently used (31) . Both methods have advantages and disadvantages. Loss of heterozygosity analysis is a PCR-based method that is technically straightforward; however, it requires normal DNA for comparison. The FISH method is also technically straightforward, and commercial probe sets are available; however, scoring can be time consuming and requires experience. The results of our study suggest that evaluation by FISH provides additional information in the form of copy number assessment of polysomy, which is not possible with loss of heterozygosity analysis. Because polysomy predicts early recurrence, FISH might therefore hold better predictive value over loss of heterozygosity for the clinical assessment of 1p/19q loss.
The prognostic value of 1p/19q loss in recurrent tumors and their response to salvage therapy is still debated. van den Bent et al. (32) showed a high response rate among recurrent 1p/19q deleted oligodendrogliomas to procarbazine, lomustine, and vincristine chemotherapy, and Brandes et al. (12) showed good response of recurrent anaplastic oligodendroglioma with 1p/ 19q loss to temozolomide; however, others showed only limited response to second-line alkylating agents, even in 1p/19q codeleted tumors (11) . Our data indicate that salvage therapy still has a beneficial effect on anaplastic oligodendroglioma with 1p/19q loss with and without polysomy and confirm the prognostic value of 1p/19q loss in recurrent anaplastic oligodendroglioma. Because the current second-line therapy is very similar to the first-line therapy, it might suggest that recurrent anaplastic oligodendroglioma with 1p/19q loss do not develop resistance during the initial treatment. Although anaplastic oligodendroglioma with loss of 1p/19q and polysomy had a worse overall survival and lower survival probability than cases with 1p/19q loss without polysomy, the difference did not reach significance. However, the trend toward shorter overall survival in the polysomy group might reach significance with a larger sample size. Therefore, results of this study need to be confirmed in a larger independent study. In summary, we have found that anaplastic oligodendroglioma with concurrent loss of 1p/19q and polysomy are associated with earlier recurrence than similar tumors lacking polysomy. Despite their early recurrence, however, such tumors can still respond to salvage therapy, and their outcome remains better than that of patients with anaplastic oligodendroglioma that have 1p/19q maintenance.
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